Loading
A phase 1/2 trial of CM336_group 1 in multiple myeloma, run by Keymed Biosciences Co.Ltd, now recruiting.
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05299424 by Keymed Biosciences Co.Ltd, with 48 participants planned, started 2022-08-09 and due to reach its primary completion in 2026-12. Interventions recorded: CM336_group 1, CM336_group 2a, CM336_group 2b, CM336_group 3a, CM336_group 3b and CM336_group 4a.
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.